Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03752398
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:23.782840+00:00
Published At
2024-07-05T00:00:00+00:00
Record Updated At
2024-07-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Melanoma (Excluding Uveal Melanoma)", "Cervical Carcinoma", "Pancreatic Carcinoma", "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Cancer", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced Solid Tumors", "Undifferentiated Pleomorphic Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-07-05"
protocolSection.identificationModule.nctId
"NCT03752398"
protocolSection.identificationModule.officialTitle
"A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb\u00ae23104 in Subjects With Selected Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Melanoma (Excluding Uveal Melanoma) (protocolSection.conditionsModule.conditions)
  • Cervical Carcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Carcinoma (protocolSection.conditionsModule.conditions)
  • Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma of the Head and Neck (protocolSection.conditionsModule.conditions)
  • Nasopharyngeal Carcinoma (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Colorectal Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Non-small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Gastric or Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Solid Tumors (protocolSection.conditionsModule.conditions)
  • Undifferentiated Pleomorphic Sarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.